Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ION251 · 1 trial · 2 indications
MTD is defined as the maximum dose at which ≤ 1 of 3 evaluable participants experiences a dose-limiting toxicity (DLT) within Cycle 1 and there are 2 of 3 or 2 of 6 evaluable participants in the next higher-dose level experiencing a DLT within Cycle 1. If no dose in the dose-escalation has 2 of 3 or 2 of 6 evaluable participants experiencing a DLT, the highest dose level is considered the MTD
RP2D is chosen based on the dose response and exposure-response analyses of the pooled clinical PK, PD, safety results, and anti-myeloma activity from both Part 1 and Part 2
| Arm | Type | Description |
|---|---|---|
| ION251 | EXPERIMENTAL | In Part 1, the dose escalation phase, increased amounts of ION251 will be administered at multiple time points by intravenous (IV) infusion during 28-day cycles. In Part 2, the determined RP2D of ION251 will be administered at multiple time points by IV infusion. |
| Name | Type | Description |
|---|---|---|
| ION251 | DRUG | ION251 administered by IV infusion |
Inclusion Criteria: 1. Aged ≥ 18 years at the time of informed consent 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 3. Measurable multiple myeloma (MM) 4. In need of systemic treatment for MM and either is refractory to or has failed treatment with, is intolerant to or ...
Top 20 of 25 competitors
ION251 is an investigational drug being studied for the treatment of relapsed or refractory multiple myeloma, a type of blood cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ION251 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS.
ION251 is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug remains investigational, meaning it is not yet approved for commercial use.
ION251 has been studied in a Phase 1 clinical trial with the identifier NCT04398485, titled 'A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma.' This trial enrolled 23 participants in the United States and has been completed.
Yes, ION251 is classified as a small molecule therapeutic. It is being investigated for its potential role in treating relapsed or refractory multiple myeloma.